Stockscreener 앱 받기
5.30
6.11%
0.305
시간 외 거래:
5.28
-0.02
-0.38%
전일 마감가:
$4.995
열려 있는:
$5.11
하루 거래량:
5.60M
Relative Volume:
0.62
시가총액:
$951.79M
수익:
-
순이익/손실:
$-26.86M
주가수익비율:
-21.56
EPS:
-0.2458
순현금흐름:
$-28.39M
1주 성능:
+7.07%
1개월 성능:
+16.48%
6개월 성능:
+229.19%
1년 성능:
+334.43%
1일 변동 폭
$5.10
$5.48
1주일 범위
$4.70
$5.60
52주 변동 폭
$0.9516
$6.14
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
명칭
Sellas Life Sciences Group Inc
전화
(646) 200-5278
주소
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
5.30 | 897.01M | 0 | -26.86M | -28.39M | -0.2458 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 개시 | Oppenheimer | Outperform |
| 2018-04-02 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 업그레이드 | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스
SELLAS Life Sciences Group Inc (SLS) Stock News & Articles - 24/7 Wall St.
SLS Eyes New Capital Streams with Securities Shelf Registration - StocksToTrade
Sellas Life Sciences: New Price Targets Signal Optimism Amid Clinical Progress - StocksToTrade
SLS Technical Analysis | Trend, Signals & Chart Patterns | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SELLAS Life Sciences Group, Inc.(NasdaqCM:SLS) added to S&P Biotechnology Select Industry Index - marketscreener.com
Penny Stocks To ResearchMarch 22nd - MarketBeat
Assessing SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price Run - Yahoo Finance
Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN
Penny Stocks To Watch NowMarch 21st - MarketBeat
BUY Rating on SELLAS: Pivotal REGAL Phase 3 Progress, Expanding AML Pipeline, and Cash Runway into 2027 Support Upside Potential - TipRanks
Investment Review: Whats the beta of SELLAS Life Sciences Group Inc stockMarket Performance Recap & High Return Trade Opportunity Guides - baoquankhu1.vn
SELLAS Life Sciences Group, Inc.: Fundamental Analysis and Financial Ratings | | US81642T2096 - marketscreener.com
SELLAS Life Sciences’ AML Pipeline Adds Key Clinical Checkpoints For Investors - simplywall.st
Form S-3ASR Sellas Life Sciences Group Inc For: 20 March - Investing.com
SELLAS (NASDAQ: SLS) registers shelf and $150M ATM with TD Cowen - Stock Titan
SLS Stock In Focus As Alliance Global Sees 92% Upside Following AML Trial Updates - Stocktwits
SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths - 24/7 Wall St.
SLS Stock Pops After-Hours As Loss Shrinks, Cash Swells — All Eyes On High Stakes AML Trial In 'Pivotal' 2026 - Stocktwits
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
SELLAS Life Sciences 2025 net loss narrows, cash position strengthens - TradingView
SLS: Strong cash position and clinical progress in AML set stage for pivotal 2026 - TradingView
[8-K] SELLAS Life Sciences Group, Inc. Report... - Stock Titan
BRIEF-SELLAS Life Sciences FY Net Income USD -26.863 Million - TradingView
SELLAS Life Sciences 2025 10-K: Revenue $0.0M, EPS $(0.25) - TradingView
SELLAS nears key leukemia trial readout after raising $42.6M in Q1 - Stock Titan
[10-K] SELLAS Life Sciences Group, Inc. Files Annual Report | SLS SEC FilingForm 10-K - Stock Titan
SLS: Net loss improved to $26.9M in 2025; strong cash reserves support ongoing clinical programs - TradingView
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Investment Recap: Will SELLAS Life Sciences Group Inc benefit from seasonality2026 Market WrapUp & Daily Growth Stock Tips - baoquankhu1.vn
SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum - Stocktwits
Sellas to present preclinical data on SLS009 at cancer conference By Investing.com - Investing.com India
SELLAS Life Sciences: SLS009’s Two-Pronged AML Clinical Approach Evaluates CDK9’s Leading Role Ahead of a Key Q4 2026 Milestone - Bitget
Sellas Life Sciences to present preclinical SLS009 data at AACR conference - TipRanks
Sellas to present preclinical data on SLS009 at cancer conference - Investing.com
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference - Bitget
Can SELLAS Life Sciences Group Inc beat the S P 500Weekly Risk Summary & Consistent Growth Equity Picks - baoquankhu1.vn
SLS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Sellas Life Sciences reports $42.6 million in warrant exercise proceeds - Investing.com Nigeria
Sellas Life Sciences Group Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Anson Funds Management LP Has $9.71 Million Position in SELLAS Life Sciences Group, Inc. $SLS - MarketBeat
SELLAS enrolls first patient in Phase 2 AML trial of SLS009 - Investing.com Nigeria
A Look At SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price Gains - simplywall.st
SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.3% HigherWhat's Next? - MarketBeat
SLS Stock Price, Quote & Chart | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SELLAS enrolls first patient in Phase 2 AML trial of SLS009 By Investing.com - Investing.com South Africa
SLS stock in spotlight: First AML patient enrolled in phase 2 leukemia trial - MSN
Sellas Says First Patient Enrolled in Phase 2 Trial of SLS009 in Acute Myeloid Leukemia - marketscreener.com
SLS Stock In Spotlight: First AML Patient Enrolled In Phase 2 Leukemia Trial - Asianet Newsable
According to the latest merger agreement terms, Signature Bank shareholders will receive an equity allocation at a ratio of 2.63 shares of Esquire Financial Holdings Inc. for each share of Signature stock. - Bitget
Major Bank Ratings | Evercore ISI: Raises Ryanair target price to $80, rating upgraded to "Outperform" - Bitget
Sellas announces enrollment of first patient in Phase 2 SLS009 trial - TipRanks
Sellas Life Sciences Group Inc (SLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):